TSO

TriSourceObserve

Slow journalism for technology, industry, and capital.

Stories

Capital Flow

Shows how policy, balance sheets, market structure, and investor expectations transmit change across industries.

AllMacro InsightsCorporate StrategyFinTech & Future AssetsSector Deep-dive
TSO / High confidence
Capital FlowCorporate Strategy

Robotics and Physical AI Funding Breaks Records: PitchBook Says Q1 2026 Raised $16.3 Billion

PitchBook says robotics and physical AI set a funding record in the first quarter of 2026, with total financing reaching $16.3 billion across 492 deals. Other sources also show continued momentum in the sector, though their reporting differs on methodology, time frame, and investment focus. What can be confirmed now is that massive funding is pushing the industry from the “experimental stage” toward the “deployment stage,” with investors paying closer attention to scaled manufacturing, paying customers, and integration-cost control.

Jun 18, 2026
Read analysis
TSO / High confidence
Capital FlowMacro Insights

Bank of Japan raises rates to a 31-year high, sparking attention over signals of further hikes

Three sources jointly confirm that the Bank of Japan raised its policy rate to 1% in June 2026, the highest level in 31 years or since 1995, and signaled possible further rate increases. The shared backdrop points to energy shocks and inflationary pressure driven by the war in the Middle East. Differences remain in wording, policy tone, and some contextual details, and certain information cannot be confirmed from the provided sources.

Jun 17, 2026
Read analysis
TSO / High confidence
Capital FlowMacro Insights

PIMCO Warns of a Credit Loss Cycle: Rising Default Risk in Lower-Quality Credit, Leveraged Loans and Private Direct Lending

In its latest annual mid- and long-term outlook, PIMCO said the credit loss cycle has reemerged and expects losses in lower-quality credit, leveraged loans and private direct lending to rise significantly. Other reports also note that AI-related capital spending could widen economic divergence and hurt lower-quality borrowers. PitchBook data show U.S. direct lending activity continues to cool, with new loans over the past three months falling to the lowest level since the second quarter of 2023.

Jun 12, 2026
Read analysis
TSO / High confidence
Capital FlowSector Deep-dive

Chinese Solar Firms Speed Up Entry into Energy Storage: Solar-Storage Integration Competes for Demand as CATL Bets on Storage as a Growth Engine

Based on three sources, Chinese solar companies are entering the battery and energy storage market dominated by CATL and BYD, and appear to be competing through integrated solar-plus-storage solutions. CATL has also publicly said energy storage will become an important growth driver for its business. In addition, U.S. market data show that solar-plus-storage accounts for a very large share of new power capacity additions. However, the specific expansion scale of leading Chinese solar firms, the detailed strategies of individual companies, and the direct business catalyst behind the “accelerated entry” cannot be fully confirmed from the given sources, and some details are not mentioned in the sources.

Jun 11, 2026
Read analysis
TSO / High confidence
Capital FlowCorporate Strategy

Japan's shareholder meeting season sees record activist proposals as capital allocation and returns take center stage

Reuters reporting shows that Japan’s listed companies received a record number of proposals from activist investors during the 2026 annual shareholder meeting season, with demands centered on improving capital allocation, boosting cash returns, and in some cases forcing executives out. A third source was a separate company voting notice unrelated to this event and was not grouped with it.

Jun 11, 2026
Read analysis
TSO / High confidence
Capital FlowSector Deep-dive

City Therapeutics Closes Approximately $99.5 Million Series B Financing to Advance RNAi Platform and Clinical Pipeline

City Therapeutics completed an approximately $99.5 million Series B financing in June 2026. Three sources consistently confirm that the amount was close to or equal to $99.5 million, with proceeds focused on advancing the RNAi engineering platform, clinical pipeline, and clinical development. There are some differences among the sources regarding the investor list and the level of detail on specific programs; any other undisclosed information is marked as “not mentioned by the source” or “cannot be confirmed from the given sources.”

Jun 10, 2026
Read analysis